Scarica l'app Stockscreener
6.39
6.50%
0.39
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ADPT Giù?
Forum
Previsione
Precedente Chiudi:
$6.00
Aprire:
$5.84
Volume 24 ore:
1.48M
Relative Volume:
1.22
Capitalizzazione di mercato:
$943.03M
Reddito:
$170.28M
Utile/perdita netta:
$-225.25M
Rapporto P/E:
-4.8045
EPS:
-1.33
Flusso di cassa netto:
$-167.02M
1 W Prestazione:
+1.43%
1M Prestazione:
+44.57%
6M Prestazione:
+99.69%
1 anno Prestazione:
+34.81%
Intervallo 1D:
$5.84
$6.505
Intervallo di 1 settimana:
$5.805
$6.93
Portata 52W:
$2.28
$7.0665
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Nome
Adaptive Biotechnologies Corp
Settore
Industria
Telefono
206-659-0067
Indirizzo
1165 EASTLAKE AVE E, SEATTLE, WA
Confronta ADPT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
6.39 | 943.03M | 170.28M | -225.25M | -167.02M | -1.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-12-21 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | Iniziato | Credit Suisse | Underperform |
| 2022-06-03 | Iniziato | Piper Sandler | Neutral |
| 2022-02-16 | Reiterato | BTIG Research | Buy |
| 2022-02-16 | Reiterato | BofA Securities | Buy |
| 2022-02-16 | Reiterato | Goldman | Neutral |
| 2022-02-16 | Reiterato | JP Morgan | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-03-03 | Downgrade | Goldman | Buy → Neutral |
| 2020-10-08 | Ripresa | BTIG Research | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-06-03 | Iniziato | Goldman | Buy |
| 2019-07-23 | Iniziato | BTIG Research | Buy |
| 2019-07-22 | Iniziato | BofA/Merrill | Buy |
| 2019-07-22 | Iniziato | Cowen | Outperform |
| 2019-07-22 | Iniziato | Goldman | Neutral |
| 2019-07-22 | Iniziato | Guggenheim | Buy |
| 2019-07-22 | Iniziato | William Blair | Outperform |
Mostra tutto
Adaptive Biotechnologies Corp Borsa (ADPT) Ultime notizie
BTIG Research Raises Adaptive Biotechnologies (NASDAQ:ADPT) Price Target to $9.00 - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.6%What's Next? - MarketBeat
Are Medical Stocks Lagging BellRing Brands (BRBR) This Year? - Yahoo Finance
Charles Schwab Investment Management Inc. Purchases 10,262 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - Defense World
Top 3 Health Care Stocks That May Collapse This Quarter - Benzinga
ADPT stock touches 52-week high at $6.71 amid robust gains By Investing.com - Investing.com South Africa
ADPT stock touches 52-week high at $6.71 amid robust gains - Investing.com
Jacobs Levy Equity Management Inc. Makes New $736,000 Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Point72 Asset Management L.P. Makes New $2.54 Million Investment in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Pier Capital LLC Grows Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions - Yahoo Finance
ADPT (Adaptive Biotechnologies) 10-Year Sortino Ratio : N/A (As of Dec. 06, 2024) - GuruFocus.com
ADPT (Adaptive Biotechnologies) 1-Year Sortino Ratio : 1.18 (As of Dec. 06, 2024) - GuruFocus.com
ADPT (Adaptive Biotechnologies) Interest Coverage : 0 (At Loss) (As of Sep. 2024) - GuruFocus.com
Adaptive Biotechnologies Corp (ADPT) With A Potential Upside Of More Than -193.16% - Stocks Register
Adaptive Biotechnologies (STU:1HM) Interest Coverage : 0 (At Loss) (As of Sep. 2024) - GuruFocus.com
Matrix Capital Management Company LP Sells 10,922,590 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies (FRA:1HM) Earnings Yield (Joel Gre - GuruFocus.com
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting - Yahoo Finance
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Short Interest Down 8.5% in November - MarketBeat
Adaptive Biotechnologies (STU:1HM) Operating Margin % : -70.27% (As of Sep. 2024) - GuruFocus.com
Adaptive Biotechnologies (STU:1HM) EPS (Diluted) : €-1.23 (TTM As of Sep. 2024) - GuruFocus.com
Cerity Partners LLC Boosts Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Rubric Capital Management LP Raises Holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Massachusetts Financial Services Co. MA Lowers Stock Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? - Benzinga
Millrace Asset Group Inc. Takes $1.40 Million Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies (FRA:1HM) Operating Margin % : -70.27% (As of Sep. 2024) - GuruFocus.com
Adaptive Biotechnologies' CFO Kyle Piskel sells $1,235 in shares By Investing.com - Investing.com Australia
Tarsus Pharmaceuticals (NASDAQ:TARS) versus Adaptive Biotechnologies (NASDAQ:ADPT) Financial Survey - Defense World
Adaptive Biotechnologies' CFO Kyle Piskel sells $1,235 in shares - Investing.com India
Head to Head Comparison: Adaptive Biotechnologies (NASDAQ:ADPT) and Ginkgo Bioworks (NYSE:DNA) - Defense World
Adaptive Biotechnologies Corp: Is ADPT Stock Worth Buying? - Stocks Register
Short Interest in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Declines By 5.5% - Defense World
William Blair Has Bullish Forecast for ADPT FY2024 Earnings - MarketBeat
Adaptive Biotechnologies Co. (NASDAQ:ADPT) Sees Significant Decrease in Short Interest - MarketBeat
Wall Street Analysts Predict a 31.36% Upside in Adaptive Biotechnologies (ADPT): Here's What You Should Know - Yahoo Finance
Rubric Capital Management LP's Strategic Acquisition in Adaptive Biotechnologies Corp - GuruFocus.com
Matrix Capital Management Reduces Stake in Adaptive Biotechnologies Corp - GuruFocus.com
Adaptive Biotechnologies (NASDAQ:ADPT) Trading Up 12.7% Following Analyst Upgrade - Defense World
Adaptive Biotechnologies (NASDAQ:ADPT) Trading 12.7% Higher After Analyst Upgrade - MarketBeat
Adaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $7.00 - MarketBeat
ADPT (Adaptive Biotechnologies) Cash From Other Investing A - GuruFocus.com
Adaptive Biotechnologies Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2024 Earnings Call Transcript - Insider Monkey
Nikko Asset Management Americas, Inc. Expands Stake in Adaptive Biotechnologies Corp - GuruFocus.com
Earnings call: Adaptive Biotechnologies posts robust MRD revenue growth - Investing.com
ARK Investment Management LLC Buys 189,134 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT) - MarketBeat
Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - MSN
Adaptive Biotechnologies Corp (ADPT) Q3 2024 Earnings Call Highl - GuruFocus.com
Adaptive Biotechnologies Corp Azioni (ADPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):